Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Sales and Divestitures: 2019-2024

Historic Gains from Sales and Divestitures for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $3.8 million.

  • BridgeBio Pharma's Gains from Sales and Divestitures fell 0.88% to $1.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.9 million, marking a year-over-year decrease of 0.88%. This contributed to the annual value of $3.8 million for FY2024, which is 5.58% up from last year.
  • Per BridgeBio Pharma's latest filing, its Gains from Sales and Divestitures stood at $3.8 million for FY2024, which was up 5.58% from $3.6 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Gains from Sales and Divestitures peaked at $3.8 million during FY2024, and registered a low of $1.6 million during FY2021.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $3.6 million (2023), whereas its average is $3.1 million.
  • In the last 5 years, BridgeBio Pharma's Gains from Sales and Divestitures soared by 110.41% in 2020 and then tumbled by 33.59% in 2021.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Gains from Sales and Divestitures stood at $2.4 million in 2020, then tumbled by 33.59% to $1.6 million in 2021, then climbed by 24.52% to $2.0 million in 2022, then skyrocketed by 84.67% to $3.6 million in 2023, then grew by 5.58% to $3.8 million in 2024.